Genemap of the human genes associated with schizophrenia

A method of diagnosing schizophrenia, the predisposition to schizophrenia, or the progression or prognostication of schizophrenia, comprising determining the amount and/or concentration of at least one polypeptide from Tables 2-4 and/or at least one nucleic acid encoding the polypeptide present in said biological sample.

-31. (canceled)

-34. (canceled)

-38. (canceled)

A method of detecting susceptibility to schizophrenia comprising detecting at least one mutation or polymorphism in the nucleic acid molecule selected from Tables 2-4 in a patient.

-42. (canceled)

-48. (canceled)

(canceled)

A method of diagnosing susceptibility to schizophrenia in an individual, comprising screening for an at-risk haplotype of at least one gene or gene region from Tables 2-4, that is more frequently present in an individual susceptible to schizophrenia compared to a control individual, wherein the presence of the at-risk haplotype is indicative of a susceptibility to schizophrenia.

-59. (canceled)

The method of claim 59, wherein determining the presence of an at-risk haplotype is performed by electrophoretic analysis, restriction length polymorphism analysis, sequence analysis or hybridization analysis.

-63. (canceled)

A method of diagnosing a susceptibility to schizophrenia, comprising detecting an alteration in the expression or composition of a polypeptide encoded by at least one gene from Tables 2-4 in a test sample, in comparison with the expression or composition of a polypeptide encoded by said gene in a control sample, wherein the presence of an alteration in expression or composition of the polypeptide in the test sample is indicative of a susceptibility to schizophrenia.

A drug screening assay comprising:

• (a) administering a test compound to an animal having schizophrenia, or a cell population isolated therefrom;
• and (b) comparing the level of gene expression of at least one gene from Tables 2-4 in the presence of the test compound with the level of said gene expression in normal cells;
• wherein test compounds which provide the level of expression of one or more genes from Tables 2-4 similar to that of the normal cells are candidates for drugs to treat SCHIZOPHRENIA disease.

-68. (canceled)

-73. (canceled)

-76. (canceled)

The method of claim 76, wherein the oligonucleotides comprises nucleic acid molecules at least 95% identical to the gene sequences from Tables 2-4.

-80. (canceled)

A method for predicting the efficacy of a drug for treating schizophrenia in a human patient, comprising:

• (a) obtaining a sample of cells from the patient;
• (b) obtaining a set of genotypes from the sample, wherein the set of genotypes comprises genotypes of one or more polymorphic loci from Tables 2-35;
• and (c) comparing the set of genotypes of the sample with a set of genotypes associated with efficacy of the drug, wherein similarity between the set of genotypes of the sample and the set of genotypes associated with efficacy of the drug predicts the efficacy of the drug for treating schizophrenia in the patient.

-84. (canceled)

-117. (canceled)

A method for identifying a gene that regulates drug response in schizophrenia, comprising:

• (a) obtaining a gene expression profile for at least one gene from Tables 2-4 in a resident tissue cell induced for a pro-inflammatory like state in the presence of the candidate drug;
• and (b) comparing the expression profile of said gene to a reference expression profile for said gene in a cell induced for the pro-inflammatory like state in the absence of the candidate drug, wherein genes whose expression relative to the reference expression profile is altered by the drug may identifies the gene as a gene that regulates drug response in schizophrenia.

-121. (canceled)

(canceled)

(canceled)

-136. (canceled)

A method of assessing a patient's risk of having or developing SCHIZOPHRENIA disease, comprising:

• (a) determining the level of expression of at least one gene from Tables 2-4 or gene products thereof, and comparing the level of expression to a normal cell;
• and (b) assessing a patient's risk of having or developing SCHIZOPHRENIA disease by determining the correlation between the differential expression of said genes or gene products with known changes in expression of said genes measured in at least one patent suffering from SCHIZOPHRENIA disease.

A method of assessing a patient's risk of having or developing schizophrenia, comprising (a) determining a genotype for at least one polymorphic locus from Tables 2-35 in a patient;

• (b) comparing said genotype of (a) to a genotype for at least one polymorphic locus from Tables 2-35 that is associated with schizophrenia;
• and (c) assessing the patient's risk of having or developing schizophrenia, wherein said patient has a higher risk of having or developing schizophrenia if the genotype for at least one polymorphic locus from Tables 2-35 in said patient is the same as said genotype for at least one polymorphic locus from Tables 2-35 that is associated with schizophrenia.

-140. (canceled)